Zurcher Kantonalbank Zurich Cantonalbank Sells 76,392 Shares of Edwards Lifesciences Co. (NYSE:EW)

Zurcher Kantonalbank Zurich Cantonalbank reduced its stake in Edwards Lifesciences Co. (NYSE:EW) by 18.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 333,679 shares of the medical research company’s stock after selling 76,392 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Edwards Lifesciences were worth $25,443,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in EW. Sequoia Financial Advisors LLC boosted its stake in shares of Edwards Lifesciences by 11.4% in the 1st quarter. Sequoia Financial Advisors LLC now owns 9,181 shares of the medical research company’s stock valued at $1,081,000 after purchasing an additional 941 shares in the last quarter. Zions Bancorporation N.A. boosted its stake in shares of Edwards Lifesciences by 34.7% in the 1st quarter. Zions Bancorporation N.A. now owns 1,738 shares of the medical research company’s stock valued at $204,000 after purchasing an additional 448 shares in the last quarter. Covestor Ltd boosted its position in Edwards Lifesciences by 18.2% during the 1st quarter. Covestor Ltd now owns 1,223 shares of the medical research company’s stock worth $144,000 after buying an additional 188 shares during the period. Mather Group LLC. boosted its position in Edwards Lifesciences by 53.5% during the 1st quarter. Mather Group LLC. now owns 7,182 shares of the medical research company’s stock worth $846,000 after buying an additional 2,503 shares during the period. Finally, Mackenzie Financial Corp boosted its position in Edwards Lifesciences by 3.1% during the 1st quarter. Mackenzie Financial Corp now owns 655,567 shares of the medical research company’s stock worth $77,173,000 after buying an additional 19,798 shares during the period. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Stock Performance

NYSE:EW opened at $87.24 on Thursday. The company has a fifty day moving average of $90.12 and a 200-day moving average of $78.14. The firm has a market capitalization of $52.51 billion, a P/E ratio of 37.93, a P/E/G ratio of 4.46 and a beta of 1.05. The company has a quick ratio of 2.40, a current ratio of 3.38 and a debt-to-equity ratio of 0.09. Edwards Lifesciences Co. has a twelve month low of $60.57 and a twelve month high of $96.12.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Tuesday, February 6th. The medical research company reported $0.64 earnings per share for the quarter, meeting the consensus estimate of $0.64. The company had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.50 billion. Edwards Lifesciences had a net margin of 23.35% and a return on equity of 23.56%. Edwards Lifesciences’s revenue for the quarter was up 13.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.64 EPS. As a group, sell-side analysts anticipate that Edwards Lifesciences Co. will post 2.76 EPS for the current year.

Analysts Set New Price Targets

EW has been the topic of several recent research reports. Wells Fargo & Company upgraded shares of Edwards Lifesciences from an “equal weight” rating to an “overweight” rating and set a $94.00 target price on the stock in a research report on Friday, February 2nd. Mizuho lifted their target price on shares of Edwards Lifesciences from $95.00 to $105.00 and gave the stock a “buy” rating in a research report on Thursday, April 11th. Morgan Stanley lifted their target price on shares of Edwards Lifesciences from $95.00 to $103.00 and gave the stock an “overweight” rating in a research report on Thursday, March 21st. Oppenheimer lifted their target price on shares of Edwards Lifesciences from $93.00 to $100.00 and gave the stock an “outperform” rating in a research report on Monday, March 18th. Finally, Royal Bank of Canada lifted their target price on shares of Edwards Lifesciences from $95.00 to $101.00 and gave the stock an “outperform” rating in a research report on Monday. One analyst has rated the stock with a sell rating, seven have given a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $91.73.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Catherine M. Szyman sold 27,000 shares of the business’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $85.62, for a total transaction of $2,311,740.00. Following the completion of the sale, the vice president now owns 34,814 shares in the company, valued at approximately $2,980,774.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Edwards Lifesciences news, CFO Scott B. Ullem sold 7,255 shares of the business’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $94.89, for a total transaction of $688,426.95. Following the completion of the sale, the chief financial officer now owns 19,074 shares in the company, valued at approximately $1,809,931.86. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Catherine M. Szyman sold 27,000 shares of the business’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $85.62, for a total transaction of $2,311,740.00. Following the sale, the vice president now owns 34,814 shares of the company’s stock, valued at approximately $2,980,774.68. The disclosure for this sale can be found here. In the last 90 days, insiders sold 194,004 shares of company stock worth $17,166,254. 1.29% of the stock is owned by corporate insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.